An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Trial Profile

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Seladelpar (Primary)
  • Indications Cholangitis
  • Focus Adverse reactions
  • Sponsors CymaBay Therapeutics
  • Most Recent Events

    • 29 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 09 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top